MP22-15 DEPRESSION IN PROSTATE CANCER PATIENTS STARTING ANDROGEN DEPRIVATION THERAPY
Notice bibliographique
Résumé
You have accessJournal of UrologyProstate Cancer: Advanced (including Drug Therapy) II (MP22)1 Apr 2019MP22-15 DEPRESSION IN PROSTATE CANCER PATIENTS STARTING ANDROGEN DEPRIVATION THERAPY Gagan Fervaha*, Jason Izard, Dean Tripp, Selina Rajan, Sarah Karampatos, Bobby Shayegan, Edward Matsumoto, Tamim Niazi, Annabel Chen-Tournoux, Vincent Fradet, Yves Fradet, Emmanuelle Duceppe, Luke Lavallee, Christopher Johnson, Joseph Chin, Darin Gopaul, Margot Davis, Jehnonathan Pinthus, Darryl Leong, and Robert Siemens Gagan Fervaha*Gagan Fervaha* More articles by this author , Jason IzardJason Izard More articles by this author , Dean TrippDean Tripp More articles by this author , Selina RajanSelina Rajan More articles by this author , Sarah KarampatosSarah Karampatos More articles by this author , Bobby ShayeganBobby Shayegan More articles by this author , Edward MatsumotoEdward Matsumoto More articles by this author , Tamim NiaziTamim Niazi More articles by this author , Annabel Chen-TournouxAnnabel Chen-Tournoux More articles by this author , Vincent FradetVincent Fradet More articles by this author , Yves FradetYves Fradet More articles by this author , Emmanuelle DuceppeEmmanuelle Duceppe More articles by this author , Luke LavalleeLuke Lavallee More articles by this author , Christopher JohnsonChristopher Johnson More articles by this author , Joseph ChinJoseph Chin More articles by this author , Darin GopaulDarin Gopaul More articles by this author , Margot DavisMargot Davis More articles by this author , Jehnonathan PinthusJehnonathan Pinthus More articles by this author , Darryl LeongDarryl Leong More articles by this author , and Robert SiemensRobert Siemens More articles by this author View All Author Informationhttps://doi.org/10.1097/01.JU.0000555600.69863.72AboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissionsReprints ShareFacebookLinked InTwitterEmail Abstract INTRODUCTION AND OBJECTIVES: Androgen deprivation therapy (ADT) for the treatment of prostate cancer has been shown, albeit not consistently, to be related to specific consequences such as incident depression. The presence of depressive symptoms in patients with advanced disease eligible for ADT is less well understood. The current study was undertaken to estimate the prevalence and predictors of depression in a contemporary sample of patients beginning ADT. METHODS: Data from the current study were drawn from the RADICAL PC study, a parent prospective cohort study conducted across 13 sites in Canada. Men with prostate cancer initiating ADT for the first time were recruited. Depressive symptoms were evaluated using the 9 item version of the Patient Health Questionnaire (PHQ-9). A score of 8 or higher on this scale represents clinically relevant depressive symptoms. To evaluate predictors of depressive symptoms, a logistic regression model was constructed including biological, psychological, and social predictor variables. RESULTS: Data from 407 patients were available at the time of this analysis. Of these, 43 (10.6%) endorsed clinically significant burden of depressive symptoms. Two variables were identified as independent predictors of depression - poor functional status (OR=5.18, p<0.001) increased depression risk, whereas being retired was found to be protective (OR=0.37, p=0.03). Indicators of advanced disease (e.g. presence of metastatic disease) were not associated with depression in either univariate or multivariate models. CONCLUSIONS: Our multi-centre study of depressive symptoms among prostate cancer patients starting ADT shows that these symptoms are already present in a sizeable sample of men. These do not seem to be affected by disease-related indicators, but rather are better predicted by psychosocial variables. Clinicians should be suspicious of poor psychological functioning especially among those prostate cancer patients with poorer functional status. Moving forward, it will be important to document the incidence and change in depressive symptoms as these patients begin ADT and are followed prospectively. Source of Funding: Prostate Cancer Canada Kingston, Canada; Hamilton, Canada; Hamiilton, Canada; Montreal, Canada; Quebec City, Canada; Montreal, Canada; Ottawa, Canada; London, Canada; Kitchener, Canada; Vancouver, Canada; Hamilton, Canada; Kingston, Canada© 2019 by American Urological Association Education and Research, Inc.FiguresReferencesRelatedDetails Volume 201Issue Supplement 4April 2019Page: e322-e322 Advertisement Copyright & Permissions© 2019 by American Urological Association Education and Research, Inc.MetricsAuthor Information Gagan Fervaha* More articles by this author Jason Izard More articles by this author Dean Tripp More articles by this author Selina Rajan More articles by this author Sarah Karampatos More articles by this author Bobby Shayegan More articles by this author Edward Matsumoto More articles by this author Tamim Niazi More articles by this author Annabel Chen-Tournoux More articles by this author Vincent Fradet More articles by this author Yves Fradet More articles by this author Emmanuelle Duceppe More articles by this author Luke Lavallee More articles by this author Christopher Johnson More articles by this author Joseph Chin More articles by this author Darin Gopaul More articles by this author Margot Davis More articles by this author Jehnonathan Pinthus More articles by this author Darryl Leong More articles by this author Robert Siemens More articles by this author Expand All Advertisement PDF downloadLoading ...
Récupéré en direct depuis OpenAlex et désinversé. Les résumés ne sont pas conservés dans cette base de données : les index inversés représentent 8,6 Go des 9,3 Go de texte de la base, et le serveur dispose de 13 Go libres.
Comment cette classification a été obtenuedéplier
Prédiction machine sur la base complète
Imitation des enseignantsNi prévalence calibrée, ni vérité terrain. Validation humaine à venir. Le volet Gemma est une étiquette directe du modèle pour chaque travail de la base, lue sur la notice réduite au titre. Le volet Codex est un classifieur appris des 10 348 étiquettes directes de Codex et calibré sur les taux pondérés de l'échantillon; les champs sans appui suffisant ne portent aucun appel Codex. Le mode candidate est l'union des deux volets; le consensus est leur intersection. Ces sorties portent le statut machine_predicted_unvalidated et ne sont pas des étiquettes humaines.
Scores du classifieur distillé par catégorie (deux têtes)
| Catégorie | Codex | Gemma |
|---|---|---|
| Métarecherche | 0,000 | 0,002 |
| Méta-épidémiologie (sens strict) | 0,000 | 0,000 |
| Méta-épidémiologie (sens large) | 0,000 | 0,000 |
| Bibliométrie | 0,001 | 0,001 |
| Études des sciences et des technologies | 0,001 | 0,000 |
| Communication savante | 0,001 | 0,000 |
| Science ouverte | 0,000 | 0,001 |
| Intégrité de la recherche | 0,001 | 0,001 |
| Charge utile insuffisante (le modèle a refusé de juger) | 0,021 | 0,003 |
Scores machine (provisoires)
Les deux têtes enseignantes du modèle étudiant, lues sur ce travail. Un score ordonne la base pour la relecture; il n'affirme jamais une catégorie, et le statut de validation accompagne chaque rangée tel quel.
Scores de référence d'un modèle non mature (critères de maturité non atteints, 7 itérations). Un score ordonne; il n'affirme jamais une catégorie.
score_only:v0-immature-baseline · tel quel depuis la passe de notation : score_only signifie que le nombre peut ordonner les travaux, et qu'aucune étiquette de catégorie n'en découleClassification
machine, non validéePrédiction automatique; un appel candidat d’une seule source (Gemma direct ou Codex distillé), pas un consensus.
Le détail, modèle par modèle et score par score, se trouve en fin de page sous « Comment cette classification a été obtenue ».